Tnuki AI agent

Intelligence Agent

Delivers Today's Plays — a finite, finishable list of accounts to reach out to today.

Try Tnuki free Start for free. No signup, no credit card.
Today's Plays
Spatial Biology · US West Pharma & Biotech
From 847 stories, 312 social posts, and 23 account deep dives analyzed overnight
MON, APR 14
3 plays
+ 3 to know about
Reach out now
Review & send →
Rashid Kumar To: Rashid Kumar, VP Translational Oncology, Gilead
“With the Tubulis deal closing, curious how the combined oncology portfolio is thinking about spatial biomarker workflows for next-gen ADC targets…”
What triggered this
Gilead to acquire ADC specialist Tubulis for up to $5B
Apr 14 — Deal validates continued ADC spend. Combined oncology portfolio opens cross-sell window for next-gen spatial biomarkers. Gilead press · Endpoints News
Reach out now
Review & send →
Shreya Patel To: Shreya Patel, Dir. Applications Development, Illumina
“The 35% single-cell jump in Q1 aligns with what we’re hearing from translational leads about capacity pressure on FFPE workflows…”
What triggered this
Illumina Q1 beat; single-cell revenue up 35% YoY
Apr 13 — Strong single-cell print implies adoption among translational teams — capacity pressure on FFPE workflows through Q2. Q1 earnings · STAT News
Reach out now
Review & send →
James Chen To: James Chen, Sr. Director, Translational Medicine, Bristol-Myers
“Saw the expanded C4 deal — curious how the platform buildout is changing near-term spatial profiling needs for the degrader-antibody pipeline…”
What triggered this
Bristol-Myers × C4 Therapeutics expand protein-degrader collaboration
Apr 12 — $200M upfront doubles BMS's TPD footprint. Translational team hiring 6 roles; platform buildout referenced in 10-Q. BMS press · 10-Q filing
Good to know
Karuna Therapeutics files 8-K with going-concern language
Apr 11 — CFO exit last week + Phase 3 CYP readout due Q2 suggest a capital raise or partnership window opening. SEC filing · BioPharma Dive
Regeneron breaks ground on $90M Tarrytown biomarker lab
Apr 10 — New-build facility + VP Varma posts on vendor demos suggest Q2 platform-evaluation window is open. Regeneron press · LinkedIn
Amgen names new Chief Scientific Officer from Genentech
Apr 9 — Executive transitions in R&D typically precede infrastructure reshuffles within 60-90 days. Q4 call pre-announced pipeline review. Amgen press · FierceBiotech
Reach out now
Review & send →
Rashid Kumar To: Rashid Kumar, VP Translational Oncology, Gilead
“With the Tubulis deal closing, curious how the combined oncology portfolio is thinking about spatial biomarker workflows for next-gen ADC targets…”
What triggered this
Gilead to acquire ADC specialist Tubulis for up to $5B
Apr 14 — Deal validates continued ADC spend. Combined oncology portfolio opens cross-sell window for next-gen spatial biomarkers. Gilead press · Endpoints News
Reach out now
Review & send →
Shreya Patel To: Shreya Patel, Dir. Applications Development, Illumina
“The 35% single-cell jump in Q1 aligns with what we’re hearing from translational leads about capacity pressure on FFPE workflows…”
What triggered this
Illumina Q1 beat; single-cell revenue up 35% YoY
Apr 13 — Strong single-cell print implies adoption among translational teams — capacity pressure on FFPE workflows through Q2. Q1 earnings · STAT News
Reach out now
Review & send →
James Chen To: James Chen, Sr. Director, Translational Medicine, Bristol-Myers
“Saw the expanded C4 deal — curious how the platform buildout is changing near-term spatial profiling needs for the degrader-antibody pipeline…”
What triggered this
Bristol-Myers × C4 Therapeutics expand protein-degrader collaboration
Apr 12 — $200M upfront doubles BMS's TPD footprint. Translational team hiring 6 roles; platform buildout referenced in 10-Q. BMS press · 10-Q filing
Good to know
Karuna Therapeutics files 8-K with going-concern language
Apr 11 — CFO exit last week + Phase 3 CYP readout due Q2 suggest a capital raise or partnership window opening. SEC filing · BioPharma Dive
Regeneron breaks ground on $90M Tarrytown biomarker lab
Apr 10 — New-build facility + VP Varma posts on vendor demos suggest Q2 platform-evaluation window is open. Regeneron press · LinkedIn
Amgen names new Chief Scientific Officer from Genentech
Apr 9 — Executive transitions in R&D typically precede infrastructure reshuffles within 60-90 days. Q4 call pre-announced pipeline review. Amgen press · FierceBiotech

Why it works

Built to replace your morning scroll.

You have seven minutes before your first meeting. Tnuki Intelligence Agent does the overnight reading so you start your day with the accounts worth calling — ranked, sourced, ready.

One read, not ten tabs.

Press releases, LinkedIn, SEC filings, trade journals, X — all synthesized into Today's Plays each morning. No scanning, no tabs, no FOMO.

Ranked by your market, not the world's.

Every account scored against your ICP and current target list. The #1 priority changes daily based on what actually happened overnight.

Every claim is one click from the source.

Each sentence links back to the article, filing, or post it came from. You verify before you reach out — nothing inferred, nothing generated.

In your inbox before your first meeting.

Delivered at 8 AM (or whenever you want it). No dashboard, no app to check, no notifications piling up — Today's Plays are waiting with your coffee.

Why reps switch

The tools Tnuki replaces.

Tool Their limitation With Tnuki
Google Alerts Keyword-only, no synthesis, scattered daily emails Today's Plays — a consolidated, ranked, finishable list with sourced context
Manual morning news scan 45+ minutes daily, easy to miss signals Delivered ready to read before coffee
ChatGPT / Perplexity briefings Hallucinates, no persistent account context Facts cited to live sources, built against your ICP
ZoomInfo / Apollo news feeds Cached DB, generic, no ranking Live web data, ranked by relevance to your market

Frequently asked

Common questions about Tnuki Intelligence Agent

How is this different from Google Alerts?
Google Alerts pushes one email per keyword match — no synthesis, no ranking, no account matching. The Intelligence Agent merges dozens of signal types into Today's Plays — a finite, ranked list of accounts to act on, with verified contacts and drafts grounded in the trigger.
What sources does it read?
Press releases, trade journals, industry publications, LinkedIn, X, hiring boards, funding databases, and public filings. The scan runs every night across your full watchlist.
Can I customize what matters most to my ICP?
Yes. The agent learns from the feedback you give it during normal chat use — which signals you follow up on, which you ignore, which accounts matter. The ranking adapts over time.
How do I know the insights are accurate?
Every sentence in every play links to its source. Click through, read the original article, and verify before you send outreach. Tnuki's anti-hallucination validator also cross-checks every claim against source material before delivery.
Try Tnuki free No signup, no credit card. Start with one sentence.

The rest of the team

Four more agents on your pipeline.

Signal Agent

Signal-based prospecting. 1,000+ sources, 24/7, intent-grounded.

Learn more →

Contact / Waterfall Agent

Verifies emails and phones across 10+ providers.

Learn more →

Drafting Agent

Writes personalized outreach from live signal context.

Learn more →

Concierge Chat

The one chat interface behind all four agents.

Learn more →

Reveal your ideal prospects.

Find your ideal prospects in under a minute for free.

Get my new pipeline Or talk to a human →